Background: Pemphigus is a serious, potentially fatal chronic autoimmune bullous disease with cutaneous and mucosal manifestations. Early diagnosis and treatment are essential.

Material And Methods: We performed a retrospective cohort study that included patients diagnosed with pemphigus in the dermatology department of Hospital Universitario Virgen Macarena, Seville, Spain, in 2005 and 2006. We reviewed demographic, clinical, and therapeutic data.

Results And Conclusions: Twenty-three patients, the majority women, were included in the study. Clinical onset usually occurred between 30 and 60 years of age. The most common variant was pemphigus vulgaris (79 %), and the sites most frequently affected were the oral mucosa, trunk, and scalp. Oral corticosteroids were the initial treatment of choice in all patients, and azathioprine and mycophenolate mofetil were given as adjuvant therapy. Complete remission was induced in 8.68 % of patients and partial remission in 91.32 %. The main complications were infections, osteopenia and osteoporosis, and cataracts.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0001-7310(09)70229-7DOI Listing

Publication Analysis

Top Keywords

hospital universitario
8
universitario virgen
8
virgen macarena
8
macarena seville
8
seville spain
8
[epidemiology pemphigus
4
pemphigus hospital
4
spain 2005-2006]
4
2005-2006] background
4
background pemphigus
4

Similar Publications

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia.

Haematologica

March 2025

Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra.

Continuous treatment with ibrutinib not only exerts tumor control but also enhances T cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib induced a decrease in the expression of exhaustion markers and the proportion of Tregs and Tfh cells normalized to levels observed in healthy donors.

View Article and Find Full Text PDF

Objectives: To investigate the levels of change fatigue among clinical nurses in public hospitals and identify the potential contributing factors.

Design: A cross-sectional, multi-stage sampling study was conducted in accordance with the STROBE guideline.

Methods: This study surveyed 2,228 nurses in China from October to December 2023 using Wen Juan Xing (www.

View Article and Find Full Text PDF

(CARV) is a pathogen with neuroinvasive potential, yet its impact on neuroinflammation and sickness behavior remains poorly understood. In this study, we investigated the neuropathological and immunological responses to CARV encephalitis in adult BALB/c mice. Mice were intranasally inoculated with either infected or uninfected brain homogenates, and clinical, histopathological, and cytokine profiles were analyzed.

View Article and Find Full Text PDF

Dysphagia is a high-profile dysfunction that often occurs after a stroke, with a prevalence of 50%-80%. Post-stroke dysphagia (PSD) often leads to serious complications such as pneumonia and malnutrition, reducing the quality of life and leading to poor prognosis or even death. PSD causes these adverse physical and psychological impairments to patients, which becomes a challenge for both patients and physicians.

View Article and Find Full Text PDF

Purpose: Combined BRAF/MEK inhibition with encorafenib (E) plus binimetinib (B) has demonstrated efficacy and tolerability in phase III clinical trials, and is the standard of care for advanced/metastatic BRAF-mutant melanoma. However, real-life evidence is limited, particularly in patients pre-treated with immune checkpoint inhibitors (ICI).

Patients And Methods: BECARE GEM 2002 was a retrospective, non-interventional study aimed at investigating the real-world effectiveness and tolerability of EB in patients with unresectable or metastatic BRAF-mutant melanoma conducted at 21 sites in Spain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!